|
AutoLumo S900 – Fully Automated Chemiluminescent Immunoassay Analyzer for Clinical Laboratories
Small- and medium-sized laboratories often face a dilemma: high-throughput automation is essential for workflow efficiency, but the footprint and cost of large platforms are prohibitive. Autobio’s AutoLumo S900 directly addresses this bottleneck.
The AutoLumo S900 is a fully automated chemiluminescent immunoassay analyzer engineered to bring high performance to constrained clinical spaces. It targets the operational reality where every square meter counts, and where downtime for manual handling directly impacts patient throughput.
The system integrates random access testing, automated reagent handling, and real-time monitoring through a touchscreen interface. Its five-stage magnetic separation and non-contact vortex mixing reduce cross-contamination risks while ensuring precision across a menu of over 150 assays—covering tumor markers, hormones, infectious diseases, and cardiac panels.
For blood banks and public health centers handling moderate sample volumes, the S900 removes the human bottleneck from repetitive washing and reagent loading. The result is a workflow that shifts technician time from benchwork to result interpretation.
From a procurement standpoint, the S900 sits in a strategic niche: it provides the automation of a high-end platform without the space or capital demands. This makes it a logical upgrade path for labs currently relying on semi-automated or manual CLIA methods.
Autobio Diagnostics, a major Chinese IVD manufacturer, demonstrates here an ability to compete with global players by focusing on modular automation and local supply chains. The S900’s component sourcing and assembly reflect China’s maturing capability in producing reliable, mid-tier diagnostic hardware.
The true test of the S900 will be its long-term serviceability in high-utilization environments. But as a platform, it signals a shift: automation is no longer reserved for top-tier hospital labs—it is becoming standard infrastructure for the clinical diagnostics middle market.
Why it matters:
For lab managers, it means higher throughput per square foot and reduced operator dependency. For procurement teams, it presents a cost-effective bridge between manual testing and fully automated core labs. And for the broader industry, it underscores China’s growing role in supplying intelligent diagnostics platforms to global markets.
View Product →
|
ScientificChina — tracking China’s science, technology, and industrial systems through the lens of real-world products.
Follow ScientificChina for deeper insight into the infrastructure behind global innovation.
Visit ScientificChina.
|
|
No products in the cart.